Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May 18th to May 21st.
May 11 2024Mainz Biomed N.V. Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week 2024 in Washington D.C. from May 18th to May 21st. DDW is recognized as a premier forum for the latest advancements in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
eAArly DETECT is a US multi-site study performed at 21 specialized gastroenterology sites that enrolled 254 clinical patients . The results show compelling performance of its multimodal screening test combining Fecal Immunochemical Test , DNA and mRNA biomarkers with a unique artificial intelligence / machine learning algorithm to differentiate between colorectal cancer , advanced adenomas , non-advanced adenomas and patient samples with no findings.
The presentation will delve into the test’s ability to accurately analyze a combination of biomarkers, improving early detection rates for both colorectal cancer and significant precancerous conditions. By leveraging this dual approach, Mainz Biomed aims to accelerate the shift from cancer detection to prevention by advancing current colorectal cancer screening practices, reflecting its commitment to reducing cancer mortality rates worldwide.
Presentation details Session Title: Cancer, Early Detection, Biomarkers for Diagnosis, Treatment and Prognosis of GI CancersTitle: "NOVEL STOOL-BASED NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER AND PRECANCEROUS LESIONS BY CLASSIC FIT COMBINED WITH NUCLEIC ACID-BASED BIOMARKER SIGNATURES."Poster #: Su1117
Key findings: First analysis of the eAArly DETECT clinical study reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. Resulting performance data confirms that this multimodal screening strategy reflects a substantial and meaningful improvement for CRC and especially AA detection, where improved sensitivity is urgently needed to decrease CRC incidence and mortality.
Colorectal Colorectal Cancer Diagnostic Endoscopy Gastroenterology Genetics Hepatology Mortality Surgery
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Good Food Guide Weekly 2024: Two Yorkshire eateries nominated for Best Local Restaurants 2024There are 16 restaurants in the country that have been nominated for Best Local Restaurants 2024 by Good Food Guide Weekly and two are based in Yorkshire.
続きを読む »
Supermarket opening times on early May bank holiday 2024Supermarket opening and closing hours for early spring bank holiday Monday, May 6
続きを読む »
Local elections 2024: Votes are counted as Labour makes early gainsLocal elections were held across more than 100 councils in England on Thursday.
続きを読む »
NFL Draft 2024 trade tracker: Chargers make early Day 2 swap to pick Ladd McConkeyFollow along here for updates on NFL Draft trades through all seven rounds.
続きを読む »
Rumored Call of Duty 2024 pre-order bonus offers early access to best modeRumors suggest a Call of Duty 2024 pre-order bonus could offer early access to the most anticipated mode for Black Ops Gulf War.
続きを読む »
2024 NBA playoff predictions: Celtics-Nuggets for the title, early West upsets and moreThe Tatum-Brown core will always have doubters until they get over the hump. Is this the year it finally happens for Boston?
続きを読む »